Enlivex Therapeutics (NASDAQ:ENLV) Trading Up 2.4% – Should You Buy?

Enlivex Therapeutics Ltd. (NASDAQ:ENLV)’s share price shot up 2.4% during trading on Thursday . The company traded as high as $1.61 and last traded at $1.52. 255,775 shares were traded during trading, an increase of 154% from the average session volume of 100,601 shares. The stock had previously closed at $1.49.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the stock. EF Hutton Acquisition Co. I upgraded shares of Enlivex Therapeutics to a “strong-buy” rating in a research note on Tuesday, August 27th. HC Wainwright restated a “buy” rating and issued a $6.00 price target on shares of Enlivex Therapeutics in a research report on Friday, September 27th.

Enlivex Therapeutics Stock Performance

The business has a 50-day moving average of $1.44 and a 200 day moving average of $1.45. The stock has a market cap of $30.68 million, a PE ratio of -1.06 and a beta of 1.04.

Enlivex Therapeutics (NASDAQ:ENLV) last issued its quarterly earnings results on Friday, August 30th. The company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.06. Equities analysts expect that Enlivex Therapeutics Ltd. will post -0.7 EPS for the current fiscal year.

Institutional Trading of Enlivex Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Armistice Capital LLC purchased a new stake in Enlivex Therapeutics in the 2nd quarter valued at about $2,415,000. Sigma Investment Counselors Inc. acquired a new stake in shares of Enlivex Therapeutics in the third quarter worth approximately $50,000. Finally, XTX Topco Ltd purchased a new stake in Enlivex Therapeutics in the second quarter valued at approximately $35,000. 1.02% of the stock is owned by hedge funds and other institutional investors.

About Enlivex Therapeutics

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial.